Strategies for pneumococcal vaccination in older adults in the coming era
- PMID: 38517265
- PMCID: PMC10962601
- DOI: 10.1080/21645515.2024.2328963
Strategies for pneumococcal vaccination in older adults in the coming era
Abstract
Pneumonia, predominantly caused by Streptococcus pneumoniae, remains a leading cause of global mortality. The 23-valent Pneumococcal polysaccharide vaccine (PPSV23) and conjugate vaccines (PCVs) are vital measures to fight against it. This paper discussed the changes in pneumococcal vaccination strategies, particularly for older adults, as vaccine effectiveness and epidemiological patterns shift. While PPSV23 maintains effectiveness against invasive pneumococcal disease (IPD), its effectiveness against pneumococcal pneumonia is declining. Conversely, PCV13 consistently demonstrates effectiveness against both IPD and pneumonia. Consequently, the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommends using PCVs, notably PCV20 and PCV15, over PPSV23. Japanese studies indicate a change in the efficacy/effectiveness of PPSV23 following PCV introduction in children, likely owing to serotype replacement and herd immunity. Additionally, recent data reveals a plateau in the reduction of PCV13 and PPSV23-covered serotypes, posing a challenge to current strategies. This paper indicates a paradigm shift in pneumonia management, acknowledging its chronic nature and potential to exacerbate other diseases. The future of pneumococcal vaccination lies in broader serotype coverage through PCVs, adapting to serotype changes driven by childhood vaccination programs. Furthermore, continuous research and vaccine development are crucial in this evolving field.
Keywords: Pneumococcal conjugate vaccine; invasive pneumococcal disease; older adults; pneumococcal pneumonia; pneumococcal polysaccharide vaccine.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Similar articles
-
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.Infect Dis Ther. 2024 Jun;13(6):1235-1251. doi: 10.1007/s40121-024-00972-9. Epub 2024 May 3. Infect Dis Ther. 2024. PMID: 38700655 Free PMC article.
-
Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs.PLoS One. 2023 Feb 15;18(2):e0281261. doi: 10.1371/journal.pone.0281261. eCollection 2023. PLoS One. 2023. PMID: 36791091 Free PMC article.
-
Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.Vaccine. 2023 Aug 31;41(38):5662-5669. doi: 10.1016/j.vaccine.2023.08.001. Epub 2023 Aug 5. Vaccine. 2023. PMID: 37544825
-
Pneumococcal vaccines for prevention of adult pneumonia.Respir Investig. 2025 Jan;63(1):96-101. doi: 10.1016/j.resinv.2024.12.007. Epub 2024 Dec 12. Respir Investig. 2025. PMID: 39672073 Review.
-
Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review.Expert Rev Vaccines. 2024 Jan-Dec;23(1):997-1010. doi: 10.1080/14760584.2024.2416229. Epub 2024 Oct 28. Expert Rev Vaccines. 2024. PMID: 39435466 Review.
Cited by
-
A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10).Vaccines (Basel). 2025 Mar 22;13(4):341. doi: 10.3390/vaccines13040341. Vaccines (Basel). 2025. PMID: 40333240 Free PMC article.
-
Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review.Healthcare (Basel). 2024 Dec 9;12(23):2490. doi: 10.3390/healthcare12232490. Healthcare (Basel). 2024. PMID: 39685112 Free PMC article. Review.
-
Novel processes to obtain pneumococcal surface proteins for vaccines.Appl Microbiol Biotechnol. 2025 Apr 10;109(1):90. doi: 10.1007/s00253-025-13440-2. Appl Microbiol Biotechnol. 2025. PMID: 40210776 Free PMC article. Review.
References
-
- Kobayashi M, Pilishvili T, Farrar JL, Leidner AJ, Gierke R, Prasad N, Moro P, Campos-Outcalt D, Morgan RL, Long SS, et al. Pneumococcal vaccine for adults aged ≥19 years: recommendations of the advisory committee on immunization practices, United States, 2023. MMWR Recomm Rep. 2023;72(3):1–6. doi:10.15585/mmwr.rr7203a1. - DOI - PMC - PubMed
-
- Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Talbot HK, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. Adults: updated recommendations of the advisory committee on immunization practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–17. doi:10.15585/mmwr.mm7104a1. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical